Drug intelligence / Profile preview

BGB601

Development stage: Discontinued
Lead developer: ADC Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

BGB601 is a proprietary anti-AXL monoclonal antibody developed by BerGenBio. This antibody was out-licensed to ADC Therapeutics for the development of an antibody-drug conjugate (ADC), ADCT-601 (mipasetamab uzoptirine), which aimed to target the AXL receptor for the treatment of advanced solid tumors. The development of ADCT-601 was ultimately discontinued in late 2022 after a Phase 1b trial did not demonstrate a favorable benefit-risk profile.

Targets

AXL (AXL receptor tyrosine kinase)

Beyond the preview

Go deeper on BGB601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BGB601.

Explore the full profile